Get access

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

Authors

  • Willibald Gerschlager MD,

    1. Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London, United Kingdom
    Search for more papers by this author
  • Peter Brown MD

    Corresponding author
    1. Institute of Neurology, Sobell Department of Neurophysiology, Queen Square, London, United Kingdom
    2. National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
    • Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom
    Search for more papers by this author

Abstract

The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic form of SPS completed a generic QoL instrument, the SF-36, and a Visual Analogue Scale (VAS) before treatment as well as 2 weeks after completion of a course of IVIG. There was significant improvement in the SF-36 subscores for pain, social functioning, general mental health, and energy–vitality with treatment. The VAS also improved significantly. We conclude that treatment with IVIG improves QoL in the SPS. © 2002 Movement Disorder Society.

Ancillary